Infectious Disease Pharmacotherapy Review

Mastering infectious disease pharmacotherapy is the cornerstone of effective patient care in pharmacy. You must bridge the gap between a microbe's identity and the patient's unique physiology, selecting agents that are potent, safe, and capable of reaching the site of infection. This review focuses on the critical principles that guide therapy—from spectrum and resistance to pharmacokinetics and stewardship—preparing you for both clinical practice and rigorous exams like the NAPLEX.

Core Drug Classes and Spectra of Activity

Antimicrobials are categorized by the pathogens they target. Antibiotics treat bacterial infections and are further classified by their spectrum of activity, which describes the range of bacteria they can kill or inhibit. A narrow-spectrum agent, like penicillin G, primarily targets Gram-positive cocci, while broad-spectrum agents, like piperacillin-tazobactam, cover Gram-positives, Gram-negatives, and anaerobes. Antivirals, such as oseltamivir or valacyclovir, interfere with viral replication cycles and are typically virus-specific. Antifungals like fluconazole (for yeasts) and voriconazole (for molds) treat fungal infections, and antiparasitics such as metronidazole (for protozoa) or ivermectin (for helminths) address parasitic diseases. Selecting an agent begins with matching its known spectrum to the most likely pathogens based on the infection site and patient factors.

For exam success, you must know classic spectrum pairings. Methicillin-resistant Staphylococcus aureus (MRSA) requires agents like vancomycin, linezolid, or doxycycline. Pseudomonas aeruginosa infections demand antipseudomonal coverage with drugs like cefepime, meropenem, or ciprofloxacin. Confusing these coverages is a common exam trap. Always ask: "Does this drug reliably reach effective concentrations at the site of infection?" For instance, while daptomycin is excellent for MRSA bacteremia, it is inactivated by lung surfactant and is not indicated for pneumonia.

Mechanisms of Action and Antimicrobial Resistance

Antimicrobials exert their effects through specific mechanisms. Antibiotics may inhibit cell wall synthesis (beta-lactams, vancomycin), protein synthesis (macrolides, tetracyclines, aminoglycosides), nucleic acid synthesis (fluoroquinolones, metronidazole), or metabolic pathways (sulfonamides, trimethoprim). Antivirals often inhibit entry, uncoating, or specific enzymes like neuraminidase or polymerase.

Resistance mechanisms are the predictable ways microbes evade these drugs. They include: 1) enzymatic inactivation (e.g., beta-lactamases breaking down penicillins), 2) alteration of the drug target (e.g., modified penicillin-binding proteins in MRSA), 3) decreased drug accumulation via efflux pumps or reduced permeability, and 4) development of alternative metabolic pathways. Resistance can be intrinsic (natural) or acquired through genetic mutation or transfer of resistance genes. Understanding these mechanisms directly informs clinical choices. For example, knowing that Klebsiella pneumoniae commonly produces extended-spectrum beta-lactamases (ESBLs) tells you to avoid third-generation cephalosporins and use a carbapenem instead.

Pharmacokinetic and Pharmacodynamic Principles

Pharmacokinetics (PK)—what the body does to the drug—is paramount in antimicrobial therapy. Key parameters include absorption, distribution, metabolism, and excretion. Pharmacodynamics (PD)—what the drug does to the pathogen—describes the relationship between drug concentration and antimicrobial effect. The critical PK/PD indices that correlate with efficacy are: time above the minimum inhibitory concentration (T > MIC) for beta-lactams; the ratio of peak concentration to MIC (Cmax:MIC) for aminoglycosides; and the area under the concentration-time curve to MIC (AUC:MIC) for vancomycin and fluoroquinolones.

These indices directly impact dosing. For a beta-lactam with a T > MIC target, frequent dosing or continuous infusion maintains drug levels. For an aminoglycoside with a Cmax:MIC target, a large, once-daily dose is optimal. You must also perform dosing adjustments for renal and hepatic impairment. For renally eliminated drugs (e.g., vancomycin, penicillins, most cephalosporins), estimate creatinine clearance using the Cockcroft-Gault equation and adjust the dose or interval. For hepatically metabolized drugs (e.g., voriconazole, erythromycin), use caution and may need to avoid or reduce dose in cirrhosis. Always check for common drug interactions; for instance, fluoroquinolones chelate with divalent cations (antacids, calcium), requiring separation of administration by 2-4 hours, and rifampin is a potent enzyme inducer that can lower concentrations of many other drugs.

Empiric vs. Targeted Therapy and Selection

Clinical decision-making hinges on transitioning from empiric to targeted therapy. Empiric therapy is initiated based on the most likely pathogens before culture results are available. It must be broad enough to cover all probable suspects, especially in severe infections like sepsis or meningitis. For example, empiric treatment for community-acquired pneumonia in a hospitalized patient often includes a beta-lactam (e.g., ceftriaxone) plus a macrolide (e.g., azithromycin) to cover typical and atypical bacteria.

Targeted therapy narrows the regimen once culture and susceptibility data return. This is the heart of antimicrobial stewardship. If a urine culture grows E. coli sensitive to nitrofurantoin and ciprofloxacin, you would choose the most narrow-spectrum, well-tolerated agent—likely nitrofurantoin for an uncomplicated cystitis. Selection criteria extend beyond spectrum and include: allergy history, organ function, drug interaction profile, cost, and patient adherence potential (e.g., once-daily doxycycline vs. four-times-daily acyclovir).

Principles of Antimicrobial Stewardship

Antimicrobial stewardship is a systematic effort to promote optimal antimicrobial use to improve patient outcomes, reduce resistance, and prevent unnecessary toxicity and cost. Core principles you must apply include: 1) Use the right drug: Match spectrum to pathogen. 2) Use the right dose: Optimize based on PK/PD and organ function. 3) Use the right duration: Treat for the shortest effective period (e.g., 5-7 days for many pneumonias, not 14). 4) De-escalate: Narrow therapy when possible. 5) Practice infection prevention: Use vaccines and proper hygiene to reduce the need for drugs.

A key stewardship intervention is the "time-out." After 48-72 hours of empiric therapy, re-evaluate the patient's clinical status and any new lab data. Ask: "Is an antimicrobial still needed? Can I narrow the spectrum? Is the dose and route optimal?" Another principle is to avoid using broad-spectrum agents for conditions that don't require them, such as prescribing azithromycin for a likely viral bronchitis.

Common Pitfalls

1. Misjudging Spectrum: Using vancomycin for all Gram-positive infections wastes a last-line agent and promotes resistance. For a susceptible Staphylococcus aureus, a beta-lactam like nafcillin or cefazolin is superior. Correction: Always confirm or consider local susceptibility patterns and use the most narrow-spectrum, effective agent.
2. Ignoring Pharmacokinetics: Prescribing oral fluconazole for a suspected candida urinary tract infection seems logical, but its excretion is primarily renal, with minimal urine concentration for the standard dose. Correction: Know which drugs achieve adequate concentrations at the primary site of infection. For fungal UTI, fluconazole requires a higher dose (e.g., 200-400mg daily).
3. Overlooking Renal/Hepatic Adjustment: Giving a standard dose of levofloxacin to a patient with a CrCl of 20 mL/min can lead to accumulation and increased seizure risk. Correction: Routinely calculate renal function and consult dosing guidelines for every antimicrobial you recommend.
4. Failing to De-escalate: Continuing empiric piperacillin-tazobactam and vancomycin for a full course after cultures only grow a sensitive E. coli. Correction: Upon receiving susceptibilities, immediately narrow therapy to the simplest, most targeted agent, such as ceftriaxone or even an oral cephalosporin if appropriate.

Summary

• Effective antimicrobial therapy requires matching the spectrum of activity of antibiotics, antivirals, antifungals, and antiparasitics to the most likely pathogen, guided by infection site and patient history.
• Understand resistance mechanisms (enzymatic inactivation, target modification, efflux pumps) to make rational drug choices and avoid ineffective agents.
• Apply PK/PD principles (T > MIC, AUC:MIC, Cmax:MIC) to optimize dosing and make essential dosing adjustments for renal and hepatic impairment to maximize efficacy and minimize toxicity.
• Initiate broad empiric therapy in serious infections, then swiftly transition to narrow targeted therapy based on culture data to practice effective stewardship.
• Antimicrobial stewardship is a professional obligation centered on using the right drug, dose, and duration, followed by de-escalation to preserve drug utility and improve patient safety.